In CLL, Ibrutinib Therapy Linked With Lower Rate of Autoimmune Cytopenia

Share this content:
Ibrutinib for treatment of chronic lymphocytic leukemia may be associated with a lower rate of treatment-related secondary autoimmune cytopenia.
Ibrutinib for treatment of chronic lymphocytic leukemia may be associated with a lower rate of treatment-related secondary autoimmune cytopenia.

Ibrutinib for treatment of chronic lymphocytic leukemia (CLL) may be associated with a lower rate of treatment-related secondary autoimmune cytopenia (AIC), according to a study published in Leukemia.1

Kerry Rogers, MD, of The Ohio State University in Columbus, OH, looked at medical records of 301 patients with CLL who were treated with ibrutinib from July 2010 and July 2014 in order to determine the effect of this therapy on the rate of AIC incidence.

Patients were reviewed for past as well as treatment-emergent cases of AIC. Prior to ibrutinib treatment, they found that 26% of patients had experienced AIC.

RELATED: Risk of Thromboembolic Events with IVIg Administration Evaluated

With a total of 468 patient-years of ibrutinib exposure, the researchers found 6 cases of treatment-emergent AIC, which corresponded with an estimated incidence rate of 13 episodes for every 1,000 patient-years of ibrutinib treatment.

In addition, 22 patients were found to be concurrently receiving therapy for AIC at the start of ibrutinib therapy, 19 of whom were successfully treated and were able to discontinue AIC therapy.

Reference

  1. Rogers KA, Ruppert AS, Bingman A, et al. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. [published online ahead of print October 7, 2015]. Leukemia. doi: 10.1038/leu.2015.273.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters